Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Nancy McKinney who wrote (5338)	8/21/1998 5:24:00 PM
From: Linda Kaplan	Respond to of 7041

Nancy, Even though Viagra has come under "lots of" criticism, the major buzz is positive because it works and is approved. Some of the same side effects that put it under criticism exist in Vasomax, which doesn't seem to work. The side effects that don't exist in Vasomax that exist in Viagra, are fairly minor, I believe. If you look at Tokyo VD's posts today you will see that he alludes to the test results on Vasomax, which I mentioned. They are not impressive. When they were released, the stock went down. Viagra's sales are slowing, but does that mean Vasomax has a better chance at market share, with a worse drug? Some, whom Viagra didn't help, would try Vasomax if it's approved. Some would try it if it isn't approved, as we can see by our Steve visitor. But since if Vasomax works at all, it works on a population with less severe problems than Viagra... you think about it yourself, in terms of its long term potential. If it were approved, I'd expect sales to be nominal after a year on the market, even if there were people who wanted to try it initially. Why do you think differently? Linda